Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Related Experimental Eli Lilly weight loss drug proves promising ... branded medications," Mochi's statement said. Mochi Health CEO Myra Ahmad told CNBC in March it planned to keep selling ...

Eli Lilly is suing four telemedicine companies selling ... In its filing, Lilly claimed Mochi CEO Myra Ahmad is not a licensed physician “Mochi Health and its unlicensed owners exercise undue ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday ... compounded versions of tirzepatide. In March, Mochi CEO Myra Ahmad told CNBC that she wasn’t worried about ...

Eli Lilly is suing four telehealth companies that ... everything at the wall to try and make a narrative,” Mochi Health CEO Dr. Myra Ahmad said in an interview. "Our mission is still the same." ...

Eli Lilly has filed a lawsuit against four telehealth ... In an email to Pharmaceutical Technology in March 2025, Mochi Health’s CEO Dr Myra Ahmad stated: “[We] will continue to provide ...

Eli Lilly is suing four telehealth companies selling ... betting that offering personalized treatments would keep it out of legal trouble, Mochi CEO Myra Ahmad told CNBC in March.

UnitedHealth's new security spending disclosures underscore how a fatal shooting in December caused companies to reassess the ...

Eli Lilly is suing four telemedicine companies selling compounded ... In its filing, Lilly claimed Mochi CEO Myra Ahmad is not a licensed physician “Mochi Health and its unlicensed owners exercise ...